Buying Cybin Stock Right Now Could Be a Brilliant Move
As the proverb goes, talent hits targets that nobody else can hit, but genius hits targets that nobody else can see. If you want your portfolio to outperform, sometimes it's necessary to look for investment opportunities in places outside the mainstream.
For example, Cybin (NYSEMKT: CYBN) is a biotech that's developing mental illness treatments derived from widely illegal psychedelic chemicals like psilocybin (best known as the active compound in "magic mushrooms"). Based on a swath of extremely positive coverage in the scientific literature, I'm of the opinion that these psychedelic therapies are going to be a tremendous force for good -- and investor returns -- over the coming years. And Cybin could well be one of the leaders in the psychedelics space, so let's take a look at why it's shaping up to be a brilliant investment.
Image source: Getty Images.
Source Fool.com
